Exercise Regimen Can Improve Fatigue in Patients With Advanced Prostate Cancer
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 18, 2025 -- For patients with advanced prostate cancer (aPC), completion of a 12-week supervised exercise regimen leads to a significant improvement in fatigue and peak exercise capacity, according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 13 to 15 in San Francisco.
Benjamin Maughan, M.D., Pharm.D., from the Huntsman Cancer Institute at the University of Utah in Salt Lake City, and colleagues conducted a prospective trial involving patients with aPC treated with an androgen deprivation therapy-based regimen and participating in a 12-week exercise program. Eligible participants had at least 4/10 tiredness, self-reported sedentary lifestyle (<90 minutes/week of exercise), no evidence of disease progression, and no chemotherapy within three months. Peak aerobic capacity, muscular strength, and endurance testing were assessed before and after 12 weeks of structured, guided exercise.
A total of 119 participants with aPC were enrolled (92 percent with metastatic disease); nine participants withdrew and 10 were lost to follow-up. The primary end point was evaluable in 72 patients. The researchers found that from baseline to 12 weeks, there was a clinically significant 5.1-point reduction in fatigue. In 76 patients who completed both aerobic fitness assessments, there was a 3.1 mL/kg/min improvement in relative peak aerobic capacity (mean of 27.5 at baseline to 30.6 at 12 weeks).
"These findings support routinely recommending exercise for and examining symptom management in patients with metastatic cancer to improve quality of life," the authors write.
Several authors disclosed ties to the pharmaceutical and biotechnology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
MicroRNA-Based Germline Signature Predicts RT-Induced Genitourinary Toxicity in Prostate Cancer
FRIDAY, April 18, 2025 -- A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced...
Prostate Cancer Screening Program Beneficial in Top Decile of Polygenic Risk Score
MONDAY, April 14, 2025 -- A prostate cancer screening program involving participants in the top decile of risk according to a polygenic risk score identifies clinically...
Risk for Long COVID Lower in Pregnant Individuals
WEDNESDAY, April 9, 2025 -- The risk for long COVID among pregnant individuals is lower than among matched nonpregnant women, according to a study published online April 1...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.